What are the most common mistakes with Tesamorelin?
The most common Tesamorelin mistakes are expecting subcutaneous fat loss (it primarily targets visceral); stopping before week 12 (the response builds over months); not measuring visceral fat at baseline so you can't tell if it worked. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Tesamorelin is limited.
Common Tesamorelin mistakes
- Expecting subcutaneous fat loss (it primarily targets visceral)
- Stopping before week 12 (the response builds over months)
- Not measuring visceral fat at baseline so you can't tell if it worked
Bloodwork worth tracking
- IGF-1 baseline + every 6 weeks
- Fasting glucose
References
- Tesamorelin for HIV-associated lipodystrophy — Falutz J et al., NEJM, 2007
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — Stanley TL et al., JAMA, 2014
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data — Falutz J et al., Journal of Clinical Endocrinology & Metabolism, 2010
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tesamorelin
Full Tesamorelin breakdownTesamorelin what it's used forTesamorelin side effectsTesamorelin how to take itTesamorelin who should avoid itTesamorelin half-lifeTesamorelin how long to workTesamorelin legal statusTesamorelin how it workscjc 1295 vs tesamorelinaod 9604 vs tesamorelinipamorelin vs tesamorelintesamorelin vs sermorelinAsk the AI Coach
Last updated 2026-06-15.